PCRX - Pacira BioSciences Inc. (PCRX) Q1 2024 Earnings Call Transcript

2024-05-07 21:14:02 ET

Pacira BioSciences, Inc. (PCRX)

Q1 2024 Earnings Conference Call

May 07, 2024, 04:30 PM ET

Company Participants

Susan Mesco - Head of Investor Relations

Frank Lee - Chief Executive Officer

Charles Reinhart - Chief Financial Officer

Jonathan Slonin - Chief Medical Officer

Christian Pedetti - Senior Manager, Investor Relations

Conference Call Participants

Gregory Renza - RBC Capital Markets

David Amsellem - Piper Sandler

Gary Nachman - Raymond James

Balaji Prasad - Barclays

Presentation

Operator

Thank you for standing by. My name is Hermione and I will be your conference operator today. At this time, I would like to welcome everyone to Q1 2024 Pacira BioScience Earnings Conference Call.

All lines have been placed on mute to prevent any background noise. After the speaker remarks, there will be a question-and-answer session. po [Operator instructions] I would now like to turn the call over to Susan Mesco, Head of Investor Relations. Please go ahead.

Susan Mesco

Thank you and good afternoon, everyone. Welcome to today's conference call to discuss our first quarter 2024 financial results. Joining me are Frank Lee, Chief Executive Officer, and Charles Reinhart, Chief Financial Officer. Jonathan Slonin, Chief Medical Officer is also here for today's question-and-answer session.

Before we begin, let me remind you that this call will include forward-looking statements based on current expectations. Such statements represent our judgment as of today and may involve risks and uncertainties. For information concerning risk factors that could affect the company, please refer to our filings with the SEC, which are available from the SEC or the Pacira website.

With that, I will now turn the call over to Frank Lee.

Frank Lee

Thank you, Susan, and good afternoon, everyone. It's been an exciting and productive time since I joined the company earlier this year, and I'm pleased to say sales are off to a solid start and on track, for all three of our trusted opioid-sparing products, which continue to make an important impact on patient's lives. This year, our priority is EXPAREL, which is what I'll focus on today. I'll also touch briefly on PCRX-201....

For further details see: